A Phase 2 interventional study of RAP-219 and Placebo in Bipolar 1 Disorder, sponsored by Rapport Therapeutics Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Rapport Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.
Among the 94 studies in Mania with a site in United States, this one is the 25th largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2025, is one of 18 in phase 2, and was the 92nd registered.
167 studies on the registry are indexed under Mania; 14 are open to participants now.
Browse Mania studies →5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Bulgaria and 10 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, China, Croatia and 8 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 33 · Phase 4 27
First in 1991; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 89 across 139 interventional studies indexed under Mania.
Median enrollment 83 across the 88 interventional studies, 155 across the 6 observational. Of the 87 that completed or were terminated, 40 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 94 have an industry lead sponsor. The 10 most frequent:
Rapport Therapeutics Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Rapport Therapeutics Inc. has 1 study filed under Mania — fewer than ten, so there is no comparison to draw.
1 of the studies in Mania with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies in Mania with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.
This is a Phase 2, proof-of-concept, multi-center, randomized, double blind, placebo-controlled study designed to evaluate the efficacy, safety and tolerability of RAP-219 in adult participants experiencing mania associated with bipolar I disorder. This is a 3-week inpatient clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with RAP-219
Drug: RAP-219
Inert comparator matching the active treatment
Other: Placebo
RAP-219 tablets administered orally, once daily for 21 days
Matching placebo tablets administered orally, once daily for 21 days
Young Mania Rating Scale (YMRS)
The YMRS is a clinician administered scale that consists of 11 items used to assess the severity of manic symptoms (total scores range from 0 to 60). The higher the YMRS score, the more severe the subject's symptoms of mania.
Time frame: Baseline to End of Treatment at Week 3
Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness Mania score
The CGI-BP Severity of Illness Mania score is a clinician-rated scale used to assess the severity of manic symptoms, depression and overall illness severity in individuals with bipolar disorder. The mania score ranges from 1 (not ill) to 7 (very severely ill), with higher scores indicating greater severity of manic symptoms.
Time frame: Baseline to end of Treatment at Week 3
Treatment Emergent Adverse Events (TEAEs)
Incidence and severity of treatment-emergent adverse events (TEAEs).
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Heart Rate
Change in Heart Rate (BPM)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Respiratory Rate
Change in Respiratory Rate (breaths per minute)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Body Temperature
Change in body temperature
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Blood Pressure
Change in blood pressure (Hg mm)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Laboratory Analytes
Change in laboratory analytes (absolute value)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Electrocardiogram (ECG) QTc interval
Changes in electrocardiogram (ECGs); QTc prolongation
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Electrocardiogram (ECG) abnormal findings
Shift table of normal to abnormal ECG findings
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Suicidality
Incidence of suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS).
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Aug 2026, 12 months.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RAP-219
Rapport Therapeutics Inc.